Replies to post #32756 on Marker Therapeutics Inc (MRKR)

[GMA13]

MRKR not providing the status report for the efficacy analysis, etc for the patients in MT-401 Cohorts 4 and 5 is very questionable behavior.
MRKR knows the aforementioned status report & they made the (by) YE commitment multiple times in their PRs, so where is the information?

The above is 1 example of MRKR intentionally withholding required information.

[PennyWorld]

Golrish1776... what are you thoughts regarding AML not needing a Phase 3 trial (as some investors on this board have stated). They have ONLY 172 participants in the Phase 2 trial, which seems very, very small for the FDA to declare that a Phase 3 trial is not needed (if the Phase 2 results are good)! Your thoughts on that? Thanks